Rising Revlimid Demand Helps Celgene's Second-Quarter EPS
Celgene Corp., of Summit, N.J., exceeded analysts' estimates modestly in its second-quarter earnings report, turning in total revenues of $1.367 billion, a 16 percent increase over the second quarter of 2011. Those revenue increases were led by growing sales of multiple myeloma blockbuster Revlimid (lenolidomide).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter